Alzamend Neuro to present at Military Health System Research Symposium

Alzamend Neuro (ALZN) will have a poster presentation at the Military Health System Research Symposium, being held from August 4-7, 2025, in Orlando, Florida. Title: Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate: Summary: The current study is designed to quantitate differences in lithium brain-to-plasma exposure in PTSD subjects between AL001 and lithium carbonate for the purpose of contributing to a composite database of analogously studied brain-plasma assessments that include data from healthy subjects and multiple additional neurodegenerative, neurological and neuropsychiatric disorders. Currently, AL001 is targeted for treatment of Alzheimer’s, BD type 1, MDD and PTSD. It’s anticipated that this study design may help target appropriate AL001 lithium systemic dosing for these indications in future studies. Using this study design, comparable target organ lithium concentrations may be quantitated between AL001 and lithium carbonate and, by equivalence inference, lithium citrate solution and syrup.